Advertisement
Canada markets closed
  • S&P/TSX

    22,116.69
    -152.43 (-0.68%)
     
  • S&P 500

    5,283.40
    +5.89 (+0.11%)
     
  • DOW

    38,571.03
    -115.29 (-0.30%)
     
  • CAD/USD

    0.7332
    -0.0008 (-0.11%)
     
  • CRUDE OIL

    73.75
    -0.47 (-0.63%)
     
  • Bitcoin CAD

    94,464.68
    +898.45 (+0.96%)
     
  • CMC Crypto 200

    1,450.38
    -17.55 (-1.20%)
     
  • GOLD FUTURES

    2,367.90
    -1.40 (-0.06%)
     
  • RUSSELL 2000

    2,059.68
    -10.44 (-0.50%)
     
  • 10-Yr Bond

    4.4020
    -0.1120 (-2.48%)
     
  • NASDAQ futures

    18,659.75
    +13.50 (+0.07%)
     
  • VOLATILITY

    13.11
    +0.19 (+1.47%)
     
  • FTSE

    8,262.75
    -12.63 (-0.15%)
     
  • NIKKEI 225

    38,736.91
    -186.12 (-0.48%)
     
  • CAD/EUR

    0.6719
    -0.0008 (-0.12%)
     

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

scPharmaceuticals, Inc.
scPharmaceuticals, Inc.

Management to host conference call and webcast at 4:30 p.m. ET

BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results for the first quarter 2024 and provide a business update.

Participants should dial 1-800-717-1738 (domestic) or 1-646-307-1865 (international) with the conference code 89054.

ADVERTISEMENT

To access the Call Me™ feature, which avoids having to wait for an operator, click here.

The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead program focuses on the subcutaneous, self-administration of IV-strength treatment in heart failure. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com

Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7579
pkelleher@lifesciadvisors.com